In a small study, patients with recurrent glioblastoma multiforme who received dual implantation of low-activity iodine-125 seeds and wafers containing carmustine (Gliadel) following surgery had a median survival of 69 weeks, with nearly one-fourth of patients (8 of 34) surviving 2 years.
Sanofi-aventis’ supplemental New Drug Application for Eloxatin (oxaliplatin) has been accepted by FDA and assigned priority review status. The sNDA proposes changes to the Eloxatin prescribing information to include long-term survival data from the MOSAIC trial.
Using the SAVI applicator for breast brachytherapy, 14 of 18 patients experienced no skin reactions, and the other four had only minor reactions that resolved quickly, Constantine Mantz, MD, reported at the 25th Annual Miami Breast Cancer Conference. Dr. Mantz, a radiation oncologist at 21st Century Oncology, Inc. Fort Myers, Florida, said that the overall cosmetic outcomes with SAVI were rated excellent.
A new study based on nearly a quarter million mammograms suggests screening mammography with computer-aided detection is more sensitive than double reads. The findings contradict a key study published last year questioning CAD's effectiveness. CAD's potential for yielding too many false positives remains controversial. Radiologists argue its misuse drives up recall rates and, with them, the number of unwarranted biopsies and overall mammography costs.
In patients with low- and intermediate-risk myelodysplastic syndromes (MDS) who have regularly received transfusions, chelation therapy improves survival, according to a study presented at ASH 2007 (abstract 249).
Pfizer Inc. has entered into an agreement to acquire Serenex, Inc., a privately held biotechnology company with an extensive compound library that targets Heat Shock Protein 90 (Hsp90). Pfizer will acquire the rights to SNX-5422, an oral Hsp90 inhibitor currently in phase I trials for the treatment of solid tumors and hematological malignancies.
In aggressive, relapsed non-Hodgkin’s lymphoma, the oral investigational mTOR inhibitor RAD001 (everolimus) has single-agent activity and is well-tolerated for long periods, according to interim results of a phase II study presented at ASH 2007 (abstract 121). Craig B. Reeder, MD, of the Mayo Clinic, Scottsdale, Arizona, reported the results of the Mayo Clinic/Dana-Farber Cancer Institute trial (MAYO-MC048G)
An 85-year-old woman presented to the emergency department with epigastric pain and nausea for 2 days. She denied vomiting, fever, or early satiety. The patient stated she had lost 10 pounds over the past 3 months. A CT scan of the abdomen revealed a 1 cm low attenuation lesion in the second portion of the duodenum.
Gabriel N. Hortobagyi, MD, was born in Hungary to a mother who had wanted to be physician. “It was a time and place in which medicine was not a suitable profession for a woman, yet I think my mother’s subliminal messages worked on me,” he said in an interview with Oncology News International.
A recent national survey found a striking increase in adverse events among Medicare cancer patients directly related to CMS’ national coverage decision on the use of erythropoiesis-stimulating agents.
Do oncologists treat their patients with colon cancer the same as they would treat themselves? Usually. A survey presented at the 2008 Gastrointestinal Cancers Symposium probed the secret world of oncologists' personal preferences (abstract 444).
A novel approach aimed at depleting host hematopoietic stem cells (HSCs) by an immunologic method may facilitate subsequent donor stem cell transplantation without the need for traditional myeloablative conditioning regimens. Agnieszka Czechowicz, a medical student conducting research in the laboratory of Irving Weissman, MD, at Stanford, discussed results of her research using murine transplantation models that could reduce the toxicity associated with traditional approaches and expand the potential applications for HSC transplantation (ASH 2007, abstract LB2).
Accurate detection of micrometastases in the lymph nodes of colorectal cancer patients appears possible with an emerging quantitative RT-PCR assay being developed by DiagnoCure Oncology Laboratories (West Chester, Pennsylvania), according to an interview with investigators at the 2008 Gastrointestinal Cancers Symposium. Data from a large prospective NIH-sponsored trial are expected to be reported at ASCO 2008.
Survival and staging in colon cancer are related to the number of lymph nodes containing metastasis. But according to several reports from the 2008 Gastrointestinal Cancers Symposium, there may be a better way to determine prognosis. The “index of metastasis,” also called the “lymph node ratio,” may be a more accurate predictor of cancer-related survival than the number of positive nodes, according to investigators who presented data at the meeting.
In unselected patients, results with the anti-epidermal growth factor receptor (EGFR) antibody panitumumab (Vectibix) in metastatic colorectal cancer patients were disappointing. However, patients with wild-type KRAS tumor status did benefit from panitumumab, according to several studies reported at the recent 2008 Gastrointestinal Cancers Symposium.
Results of a phase III trial show for the first time a significant survival advantage in patients with high-risk myelodysplastic syndrome who were treated with the DNA methylation inhibitor azacitidine (Vidaza). Pierre Fenaux, MD, of the Hôpital Avicenne, Bobigny, France, presented these findings on behalf of the International Vidaza High-Risk MDS Survival Study Group at ASH 2007 (abstract 817).
Phase III study results show that addition of the proteosome inhibitor bortezomib (Velcade) to standard chemotherapy significantly improves outcomes in patients with newly diagnosed multiple myeloma who are not eligible for high-dose chemotherapy and stem-cell transplantation (SCT).
Multiple myeloma patients receiving lenalidomide (Revlimid) plus dexamethasone had improved responses, longer time to progression, and improved overall survival than those receiving dexamethasone alone in pooled phase III clinical trial results. Donna Weber, MD, of M.D. Anderson Cancer Center, presented the findings at ASH 2007 (abstract 412).
Breast cancer is the most common life-threatening malignancy in women, and the second leading cancer killer of women, claiming the lives of over 40,000 American women annually. Breast cancer incidence increases with advancing age until age 80, and the median age at diagnosis is 61.
When colorectal cancer metastasizes to the liver, hepatic resection can offer a survival benefit and even a "cure" in a fraction of patients. Five-year overall survival in some recent series approaches 60%. But the role of neoadjuvant chemotherapy in this group of patients has not been well established
As a young boy, Vincent DeVita dissected frogs on the front steps of his parents' house in Yonkers. In the eyes of his encouraging mother, he was already a budding physician fascinated by the internal complications of life.
In a pivotal phase III study, rituximab (Rituxan) in combination with standard chemotherapy significantly increased time to progression in patients with previously untreated chronic lymphocytic leukemia
Preliminary results suggest that immunotherapy with recombinant interleukin-2 (rIL-2) may prolong survival in younger patients with acute myeloid leukemia in first remission. However, the high rate of refusal or discontinuation of such therapy presents challenges for its acceptance
A new formulation of Emend has entered oncology's antiemetic armamentarium. Emend (fosaprepitant dimeglumine, Merck) for Injection received US Food and Drug Administration approval in late January for use in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with initial and repeated courses of moderate- or high-emetogenic chemotherapies, including high-dose cisplatin.
Modern medicine has made most infectious diseases of bacterial origin easily managed. However, research has shown that chronic infections caused by a handful of viruses, bacteria, and parasites play a significant role in the development of certain cancers.
A novel frontline regimen has shown efficacy in high-risk patients with chronic lymphocytic leukemia, with no significant increase in hematologic toxicity, compared with historical data on the standard regimen
A 31-year-old man presented in May 2007 with generalized painful, ulcerated, and necrotic papules and plaques worsening for the last few months. He had been diagnosed with mycosis fungoides in October 2005. Treatments included topical corticosteroids and psoralen with ultraviolet A light therapy (PUVA), with the latter being discontinued because of the development of blisters. For the last 6 months, he had been treated with oral bexarotene (Targretin), with initial improvement of his skin lesions.
Palliative care for patients and their families across the cancer disease trajectory-from diagnosis, through survivorship, to end of life-is essential for quality cancer care. In their excellent article, Ferrell and Virani emphasize the important role of oncology nurses in providing palliative care, and they present the National Consensus Project (NCP) Guidelines[1] and the National Quality Forum (NQF)[2] preferred practices as a roadmap for all oncology nurses to use in their practice.
Patients with cancer have significant needs for palliative care, including pain and symptom management and psychosocial and spiritual support. The experience of cancer has an impact on family caregivers as well, and palliative care needs exist from diagnosis through survivorship and end-of-life care. Oncology nurses have opportunities to integrate palliative care into disease-focused care.